Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment

Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment

There are limited data available about the durability of the immune response after administration of the widely used adenovirus-vectored ChAdOx1-nCoV-19 vaccine in cancer patients. This prospective longitudinal observational study analyzed follow-up data of immunogenic responses 12 weeks after the s...

Full description

Bibliographic Details
Main Authors: Passakorn Wanchaijiraboon, Nattaya Teeyapun, Nussara Pakvisal, Panot Sainamthip, Thiti Susiriwatananont, Nicha Zungsontiporn, Nungruthai Suntronwong, Preeyaporn Vichaiwattana, Worata Klinsawat, Nasamon Wanlapakorn, Suebpong Tanasanvimon, Virote Sriuranpong, Yong Poovorawan, Sutima Luangdilok
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Vaccines
Subjects:
COVID-19 vaccine
Omicron
ChAdOx1
cancer
immunogenicity
SARS-CoV-2
Online Access:https://www.mdpi.com/2076-393X/10/10/1662

Internet

https://www.mdpi.com/2076-393X/10/10/1662

Similar Items